Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. AIM ImmunoTech Inc. (AIM) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.AIM ImmunoTech Inc. is one of 932 individual stocks in the Medical sector. Collectively, these com ...

GARLAND, Texas, Jan. 6, 2026 /PRNewswire/ -- Massimo Group (NASDAQ: MAMO), a manufacturer and distributor of powersports vehicles and electric utility products, today announced it will exhibit at AIM Expo, North America's premier powersports industry event, taking place in Anaheim, California January 7-9, 2026. The Company will showcase its new 2026 product lineup and engage with both existing and prospective dealer partners. At the show, Massimo will feature its 2026 Sentinel Series fully enclosed HVAC UT ...

Core Viewpoint - Premarket trading is showing notable activity with significant price movements indicating potential investment opportunities before the market opens [1] Group 1: Premarket Gainers - SMX (Security Matters) Public Limited Company (SMX) is up 39% at $22.80 [3] - Rubico Inc. (RUBI) has increased by 21% to $1.30 [3] - Aimei Health Technology Co., Ltd (AFJK) is up 19% at $76.80 [3] - Sable Offshore Corp. (SOC) has risen 19% to $10.81 [3] - Diginex Limited (DGNX) is up 18% at $4.95 [3] - Sidus Space, Inc. (SIDU) has increased by 18% to $3.71 [3] - SELLAS Life Sciences Group, Inc. (SLS) is up 16% at $4.40 [3] - Alchemy Investments Acquisition Corp 1 (ALCY) has risen 14% to $16.24 [3] - Greenidge Generation Holdings Inc. (GREE) is up 11% at $1.65 [3] - Enigmatig Limited (EGG) has increased by 5% to $5.52 [3] Group 2: Premarket Losers - Intelligent Bio Solutions Inc. (INBS) is down 11% at $8.48 [4] - ZW Data Action Technologies Inc. (CNET) has decreased by 11% to $1.20 [4] - Nuvve Holding Corp. (NVVE) is down 9% at $2.31 [4] - ESH Acquisition Corp. (ESHA) has fallen 8% to $17.59 [4] - LZ Technology Holdings Limited (LZMH) is down 6% at $1.55 [4] - Oriental Rise Holdings Limited (ORIS) has decreased by 4% to $1.43 [4] - Cango Inc. (CANG) is down 3% at $1.45 [4] - Massimo Group (MAMO) has fallen 2% to $3.90 [4] - Anghami Inc. (ANGH) is down 2% at $3.68 [4] - AIM ImmunoTech Inc. (AIM) has decreased by 2% to $1.10 [4]

Core Viewpoint - AIM ImmunoTech Inc. announced a stock dividend of one share for every 1,000 shares of outstanding common stock and for every outstanding option or warrant that has a right to receive stock dividends, with the record date set for January 9, 2026, and distribution on January 13, 2026 [1]. Group 1: Stock Dividend Details - The stock dividend will be issued to stockholders and holders of Alternate Securities, with fractional shares rounded down and cash distributed for any remaining fractions based on a share price of $1.305, the average price on December 29, 2025 [2]. - Stockholders will not need to take any action to receive the stock dividend, as their accounts will be credited automatically, and brokers will receive the additional shares on behalf of stockholders [3]. Group 2: Company Overview - AIM ImmunoTech Inc. is focused on the research and development of therapeutics for various cancers, immune disorders, and viral diseases, including COVID-19, with its lead product being Ampligen (rintatolimod), a first-in-class investigational drug [4].

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

VIRGINIA BEACH, Va.--(BUSINESS WIRE)--The Aviation Institute of Maintenance (AIM) announced today that it will be the first aircraft maintenance trade school featured on Season 16 of Amazon Prime Video's hit series The College Tour. Filming begins December 8, 2025, marking a meaningful milestone for AIM and reflecting the rising national momentum behind aviation maintenance careers and skilled trades education. Production will take place at AIM's Hasbrouck Heights campus, highlighting the schoo. ...

AIM ImmunoTech Conference Summary Company Overview - **Company**: AIM ImmunoTech (NYSEAM:AIM) - **Lead Asset**: Ampligen, a drug with potential in immuno-oncology, effective as both a monotherapy and a synergistic enhancer to checkpoint inhibitors across various solid tumors [8][12] Core Points and Arguments - **Ampligen's Potential**: - Demonstrated strong impact in improving response rates for patients who are refractory to checkpoint inhibitors [8] - Alters tumor microenvironment to enhance visibility to immune system, transforming "cold tumors" into "hot tumors" [11][12] - **Strategic Focus on Pancreatic Cancer**: - AIM has prioritized pancreatic cancer as its lead indication due to the high unmet medical need and potential for significant impact on patient survival [13][15] - The company aims to leverage its data showing Ampligen's ability to extend overall survival in pancreatic cancer, both as a monotherapy and in combination with AstraZeneca's Durvalumab [15][19] - Orphan drug designations received in the U.S. and Europe provide market exclusivity, enhancing the business opportunity [16][17] - **Market Context**: - Over 500,000 deaths annually from pancreatic cancer, with a low survival rate, highlighting the critical need for effective treatments [19] - The oncology sector is where significant biotech deals occur, with potential for billion-dollar partnerships [14][28] - **Clinical and Regulatory Strategy**: - AIM is working towards initiating a Phase 3 trial in pancreatic cancer, ideally in conjunction with checkpoint inhibitors [24][25] - The company has treated 57 subjects, demonstrating the ability to extend overall survival beyond standard care [25] - **Upcoming Milestones**: - Anticipation of a positive year-end report, which is expected to be a significant inflection point for the company [28] - Plans to find a big pharma partner to support the Phase 3 trial and capitalize on the research and development efforts [26][28] Other Important Content - **Collaborations**: - Successful collaborations with Merck and AstraZeneca have been crucial for advancing Ampligen's development [30] - Data from independent research institutions supports the efficacy of Ampligen in various cancers, not limited to pancreatic cancer [29][30] - **Quality of Life Considerations**: - Ampligen is noted for improving the quality of life for patients undergoing treatment, which is particularly important for those facing severe malignancies [15][16] - **Company's Position**: - AIM is a small biotech company with limited resources but is making significant strides in oncology research [31] - The CEO expressed gratitude towards collaborators, investors, and the research community for their support [39][40] This summary encapsulates the key insights from the AIM ImmunoTech conference, focusing on the company's strategic direction, clinical developments, and market opportunities in the context of pancreatic cancer and broader oncology applications.

纽约, Dec. 03, 2025 (GLOBE NEWSWIRE) -- 全球领先的人工智能驱动型字幕生成与音频描述技术提供商 AI-Media 今日宣布，正式启动全面的 ADA 第二章合规计划。该计划旨在帮助美国各州及地方政府，满足联邦政府最新敲定的数字内容无障碍合规要求。 2024 年 4 月，美国司法部最终敲定《ADA 第二章网络及移动设备无障碍规则》(ADA Title II Web and Mobile Accessibility Rule)，要求公共实体的所有数字服务均符合 WCAG 2.1 AA 级标准。 合规截止日期方面，服务人口超过 5 万人的实体需在 2026 年 4 月 24 日前达标，规模较小的辖区及特别区则需在 2027 年 4 月 26 日前达标。 上述规则要求网站、移动应用程序及多媒体内容（包括字幕、文字记录及音频描述）具备无障碍访问功能。 为协助政府机构应对合规期限，AI-Media 启动了一项为期数月的宣教计划，提供实用工具并推广其解决方案。这些解决方案旨在简化合规流程，助力机构大规模高效达成合规要求。 “公共实体正面临数十年来最重大的无障碍转型之一，”AI-Media 联 ...

Core Insights - AI-Media has launched an ADA Title II Compliance Initiative to assist state and local governments in meeting new federal accessibility requirements for digital content [1][4] - The U.S. Department of Justice finalized the ADA Title II Web and Mobile Accessibility Rule, mandating compliance with WCAG 2.1 Level AA, with deadlines starting April 24, 2026, for larger entities [2] - AI-Media's initiative includes a 10-Point ADA Title II Compliance Checklist and highlights its LEXI Text and LEXI AD technologies as essential tools for compliance [4][6] Compliance Initiative - The initiative aims to provide educational resources and practical tools to help government agencies prepare for upcoming compliance deadlines [3] - AI-Media will host a national webinar on January 20, 2026, to discuss accessibility requirements and how AI solutions can facilitate compliance [5] Technology Solutions - LEXI Text offers AI-powered captioning and transcription services to meet WCAG captioning and transcript requirements [11] - LEXI AD provides AI-driven audio description with advanced customization options, crucial for meeting WCAG 2.1 AA standards for prerecorded video [11]